
Tumor Immunology and Immunotherapy – Molecular Methods (Volume 629)
Author(s): Lorenzo Galluzzi (Editor), Nils-Petter Rudqvist
- Publisher: Academic Press
- Publication Date: 17 Nov. 2019
- Language: English
- Print length: 552 pages
- ISBN-10: 0128186712
- ISBN-13: 9780128186718
Book Description
Tumor Immunology and Immunotherapy – Molecular Methods, Volume 629, the latest release in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Chapters in this release include Droplet digital PCR for measuring circulating tumor-derived DNA, Detection and quantification of cytosolic DNA, Methods to detect endogenous dsRNA induction and recognition, Quantification of eIF2alpha phosphorylation during immunogenic cell death, Assessment of annexin A1 release during immunogenic cell death, Luciferase-assisted detection of extracellular ATP in the course of ICD, The P2X7 receptor: structure and function, and much more.
- Contains the authority of authors who are leaders in their field
- Provides a comprehensive source on new methods and research in enzymology
Editorial Reviews
Review
The latest volume in the Methods in Enzymology series, with this release focusing on tumor immunology and immunotherapy
About the Author
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.
Wow! eBook


